Literature DB >> 16393710

Melatonin entrains free-running blind people according to a physiological dose-response curve.

Alfred J Lewy1, Jonathan S Emens, Bryan J Lefler, Krista Yuhas, Angela R Jackman.   

Abstract

The specific circadian role proposed for endogenous melatonin production was based on a study of sighted people who took low pharmacological doses (500 microg) of this chemical signal for the "biological night": the magnitude and direction of the induced phase shifts were dependent on what time of day exogenous melatonin was administered and were described by a phase-response curve that turned out to be the opposite of that for light. We now report that lower (physiological) doses of up to 300 microg can entrain (synchronize) free-running circadian rhythms of 10 totally blind subjects that would otherwise drift later each day. The resulting log-linear dose-response curve in the physiological range adds support for a circadian function of endogenous melatonin in humans. Efficacy of exogenous doses in the physiological range are of clinical significance for totally blind people who will need to take melatonin daily over their entire lifetimes in order to remain entrained to the 24 h day. Left untreated, their free-running endocrine, metabolic, behavioral, and sleep/wake cycles can be almost as burdensome as not having vision.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16393710     DOI: 10.1080/07420520500398064

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  26 in total

1.  A three pulse phase response curve to three milligrams of melatonin in humans.

Authors:  Helen J Burgess; Victoria L Revell; Charmane I Eastman
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

2.  Combination of light and melatonin time cues for phase advancing the human circadian clock.

Authors:  Tina M Burke; Rachel R Markwald; Evan D Chinoy; Jesse A Snider; Sara C Bessman; Christopher M Jung; Kenneth P Wright
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

3.  Jet lag: current and potential therapies.

Authors:  Mary Choy; Rebecca L Salbu
Journal:  P T       Date:  2011-04

Review 4.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

5.  Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.

Authors:  Nalaka S Gooneratne; Alena Y Z Edwards; Chen Zhou; Norma Cuellar; Michael A Grandner; Jeffrey S Barrett
Journal:  J Pineal Res       Date:  2012-02-21       Impact factor: 13.007

Review 6.  Circadian misalignment in mood disturbances.

Authors:  Alfred J Lewy
Journal:  Curr Psychiatry Rep       Date:  2009-12       Impact factor: 5.285

7.  Review of disrupted sleep patterns in Smith-Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion.

Authors:  Eilis A Boudreau; Kyle P Johnson; Angela R Jackman; Jan Blancato; Marjan Huizing; Claude Bendavid; Marypat Jones; Settara C Chandrasekharappa; Alfred J Lewy; Ann C M Smith; R Ellen Magenis
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

Review 8.  Circadian rhythm disturbances in depression.

Authors:  Anne Germain; David J Kupfer
Journal:  Hum Psychopharmacol       Date:  2008-10       Impact factor: 1.672

9.  Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  R Robert Auger; Helen J Burgess; Jonathan S Emens; Ludmila V Deriy; Sherene M Thomas; Katherine M Sharkey
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

10.  Diagnostic and Treatment Challenges of Sighted Non-24-Hour Sleep-Wake Disorder.

Authors:  Roneil G Malkani; Sabra M Abbott; Kathryn J Reid; Phyllis C Zee
Journal:  J Clin Sleep Med       Date:  2018-04-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.